# Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

> **NCT05720260** · PHASE2 · RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Premenopausal Breast Cancer
- Metastatic Breast Cancer
- ER Positive Breast Cancer

## Interventions

- **DRUG:** Goserelin
- **DRUG:** Fulvestrant
- **DRUG:** Capivasertib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05720260
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-17
- **Primary completion:** 2024-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720260, "Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05720260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*